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Abstract: The 2014 outbreak clearly showed that Ebola viruses (EBOV) remain a substantial threat 
for public health. The mainstay of management of patients with Ebola disease is isolation of patients 
and use of strict barrier nursing procedures; the present treatment strategies are mainly symptomatic 
and supportive (fluid resuscitation, antypyretics, antidiarrheal drugs). Currently, there is no approved 
therapy for Ebola hemorrhagic fever (EHF), however several advanced treatment options were tested 
in animal models (on non-human primates or rodents). They include use of both symptomatic (e.g. 
use of tissue factor inhibitors — rhNAPc2, rhAPC — to abolish coagulopathy) and specific antiviral 
approaches: e.g. monoclonal anti EBOV antibodies (ZMapp, MB-003), phosphorodiamidate morpholino 
oligomers (PMOs), liposomes containing siRNA (LNP-siRNA:TKM-Ebola) and small molecule inhibitors 
(e.g. BCX4430, favipiravir). The scope of this article is to briefly review the most promising therapeu-
tics for EHF, based on the data coming from rare clinical reports, studies on animals and results 
from in vitro models.
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PHARMACOBIOLOGY OF EBOLA VIRUS INFECTION
Ebola virus (EBOV), the culprit of current deadly epidemic in West Africa, has 
been one of the most feared pathogens, causing severe hemorrhagic fever (EHF) 
with high mortality [1]. The genus Ebolavirus (family: Filoviridae, order: Mononega-
virales) includes five species: Zaire ebolavirus (ZEBOV), Sudan ebolavirus (SUDV), 
Reston ebolavirus (RESTV), Tai Forest ebolavirus (TAFV) and Bundibugyo ebolavi-
rus (BDBV), each pathogenic for humans except RESTV, which has been shown to 
be pathogenic only for non-human primates [2]. All EBOV species have been se-
quenced and their evolutionary characteristics have been reported [3]. The EBOV is 
a lipid enveloped virus of filamentous shape with a mean unit length of 1200 nm [3]. 
The single 19-kb negative sense RNA encodes seven proteins: nucleoprotein (NP), 
glycoprotein (GP, produced also in its soluble truncated form — sGP, through 
RNA editing), RNA dependent RNA polymerase (L) and four matrix proteins (VP24, 
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VP30, VP35 and VP40). The inner matrix proteins — VP30 and VP35 and the 
polymerase (L) form the complex involved in transcription and replication, while 
the VP40 and VP24 are linked to the ribonucleoprotein complex at the inner sur-
face of lipid envelope, which is originated from the host cell [2]. The viral envelope 
contains only the highly glycosylated glycoproteins, assembled after cleavage of 
precursor polyprotein by cellular furin-like enzyme, as a trimeric spikes consist-
ing of two fragments: extracellular protein (GP1) and membrane-anchored protein 
(GP2). While the GP1 is believed to play sole crucial role in virus attachment to 
the various host cells, several potential candidates for GP1 receptor/co-receptors 
on cells have been characterized: transferrin, folate receptor, members of the 
Tyro3 family of receptor tyrosine kinases (Axl, Dtk, Mer), dendritic cell-specific 
intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN) and T-cell im-
munoglobulin and mucin domain (TIM-1) proteins [4, 5]. Following binding the 
virus is taken up into the cells via micropinocytosis. The cholesterol transport 
protein Niemann-Pick C1 (NPC1) seems to act as an intracellular receptor for 
EBOV after cleavage of viral GP by low PH-dependent cathepsins B and L. Such 
diversified entry mechanisms surely account for broad cell tropism of EBOV [6]. It 
is generally accepted that monocytes/macrophages and dendritic cells are prima-
ry targets for EBOV, however virus quickly disseminates to endothelial cells and 
subsequently can be found in various organs (lymph nodes, spleen, liver). Such 
spreading coincides with dysregulation of the immune/inflammatory mechanisms 
(fever, cytokine storm, complement activation, overproduction of nitric oxide etc.), 
severe endothelial injury (vascular leakage, bleeding), liver failure (hepatocellular 
necrosis, coagulopathy, DIC) and adrenal gland dysfunction (impairment of corti-
costeroid production). Clinically, EBOV infection is characterized by abrupt onset 
of flu-like symptoms after incubation period of 2–21 days. These are accompa-
nied by anorexia and gradually increasing nausea, emesis and diarrhea. In few 
days 25–52% of patients develop maculo-papulary rash and petechiae. Swelling 
of lymph nodes as well as enlargement of kidneys, testes/ovaries or brain edema 
may occur. In later stages, patients demonstrate hypotension and shock, muco-
sal hemorrhages (typically from GI tract or conjunctival) and multi-organ failure 
(particularly renal and liver). Case fatality rates associated with EBOV infection 
range between 50–90% and mainly depend on virus species, with ZEBOV being 
the most deadly. Long period of convalescence is often associated with complica-
tions like hepatitis, uveitis, myelitis and psychotic reactions [1, 2].
The great role in pathobiology of EHF plays deregulated, exaggerated response 
of host organism. EBOV infection quickly triggers massive expression of inflam-
matory mediators including nitric oxide and reactive oxygen species (which are 
partially responsible for microvascular complications) and a whole bunch of pro- 
and anti-inflammatory proteins: interferons, interleukins (e.g. IL-2, 6, 8, 10), tu-
mor necrosis factor alpha (TNFa), chemokines (e.g. macrophage chemoattractant 
protein-1) leading to immunological paralysis that contributes to the progression 
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of disease [1, 2]. Noteworthy, Ebola virus developed multiple mechanisms of dis-
abling of effective, immune anti-viral response (e.g. VP24 and VP34-dependent 
inhibition of interferon expression and action in host cells, epitope shielding due 
to GP glycosylation, down-regulation of MHC-class II and co-stimulatory mole-
cules on dendritic cells) [7]. An important difference between EBOV and other 
Mononegavirales is the production of large quantities of soluble GP, however its 
exact pathological role in EHF remains unresolved.
MANAGEMENT STRATEGIES
The mainstay of current management is isolation of patients and use of strict bar-
rier nursing procedures. Present treatment strategies are mainly symptomatic and 
supportive. In general, the typical antiviral drugs like interferons (except slight 
positive effect of beta-interferone [8]) or ribavirine are not effective [9]. Although 
a number of effective chemotherapeutic/chemopreventive agents have been iden-
tified in various animal models – on Non-Human Primates (NHPs) and Small An-
imal Models (SAM) — as well as several interesting compounds have been found 
to interfere with EBOV life cycle in cultured cells in vitro, by far there is no ap-
proved specific therapy for EHF.
SYMPTOMATIC AND SUPPORTIVE CARE
The critical analysis of various supportive regimens documented in published 
reports after 34 recognized EHF outbreaks since 1967 was provided by Clark 
et al. [10]. As the early EHF signs are difficult to distinguish from other febrile 
infections, patient care typically followed the use of antypyretics (paracetamol, 
aspirin, dipyrone), antibiotics (tetracycline, chloramphenicol, penicillin, ampicillin, 
ciprofloxacin) and antimalarial drugs (chloroquine, amodiaquine, pyrimethamine, 
atovaquon-proguanil, artemisinin combination therapy). Antibiotics were given 
also later in the course of disease to prevent or treat secondary bacterial infec-
tions. Other symptomatic treatment, depending on clinical needs, included oral/
intravenous fluid therapy, antidiarrheal drugs, antiemetics, analgesics, sedatives 
and antipsychotic drugs to reduce anxiety and agitation. In severe cases treatment 
included transfusion of blood (from regular donors or convalescent patients) and 
blood products (whole blood, packed red blood cells, fresh frozen plasma, plate-
lets) and various blood-derived regulators of coagulation (clotting factors, fibrin-
ogen, prothrombin, proconvertin, Stuart-factor, antihemophilic globulin B). Anti-
coagulants (heparin) and rheological agents (pentoxyfylline) were administered to 
some patients to prevent/treat disseminated intravascular coagulation. There are 
no clinical trials providing evidence –based guidance regarding basic supportive 
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care. The data coming from the studies on rhesus macaques suggest that fluid re-
placement may limit renal injury, but has no impact on overall mortality [11, 12]. 
It is generally accepted, that as pathological process of EHF resembles that of 
severe sepsis, therefore aggressive supportive care protocols, with early fluid re-
suscitation may represent reasonable strategy of treatment. However, it should 
be noted that aggressive fluid therapy, given endothelial injury in EHF patients, 
may pose the risk of pulmonary edema [10].
Severe coagulation disorder, developing due to massive exposure of tissue fac-
tor (TF) on injured endothelium is one of the most prominent features of advanced 
EHF, therefore the possibility of inhibiting this pathway has been considered as 
an important therapeutic approach. In this regard, agents that may reduce mor-
tality without influencing directly virus replication include recombinant nematode 
anticoagulant protein c2 (rNAPc2) and recombinant human activated protein C 
(rhAPC), inhibitors of factor VIIa-TF complex [13, 14]. Geisbert et al. demonstrat-
ed that in rhesus macaques infected with EBOV, early post exposure treatment 
with rNAPc2 (daily s.c. injection of 30 µg/kg) provided partial protection, as it 
resulted in 33% survival rate and 3,4-day increase in time-to-death in treated 
animals in a typically 100% lethal model [15]. Importantly, rNAPc2 is currently 
in phase II clinical trials in orthopedic surgery and coronary revascularization 
and shows good safety record. 
The experiments with EBOV in NHPs demonstrated significant decrease in 
circulatory levels of protein C [16]. The recombinant human activated protein 
C (drotrecogin alpha, rhAPC) given 30–60 min after EBOV infection of rhesus 
macaques and continuing for next 7 days (in daily s.c. injections of 30 µg/kg) 
provided 20% survival and almost 4-day increase of in time-to-death of treated 
animals. The current status of rhAPC is unclear — it was formerly approved for 
the treatment of patients with advanced septic shock, however taking into grant-
ed the risk of adverse effects (bleeding) the Cochrane Review in 2011 not recom-
mended clinical use the hrAPC in this indication [14]. 
Thus, both TF inhibitors represent promising advanced symptomatic therapies 
(not directly targeting the virus) and should be probably considered for use in 
EHF treatment in conjunction with specific anti-EBOV compounds.
SPECIFIC ANTI-EBOV TREATMENT
An attractive treatment option that has been applied to EHF is the use of pas-
sive immunization, however the first attempts were not successful: despite some 
positive effects in SAM, antibody treatment with equine immunoglobulin against 
EBOV or with recombinant human monoclonal antibody did not protect NHPs [16]. 
Human convalescent blood or serum has been used in NHPs, but the results were 
controversial [17]. During 1995 outbreak in Kikwit (DRC), human convalescent 
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plasma was given to 8 patients with proven Ebola disease and only 1 patients 
died, however subsequent studies could not confirm clear benefit conferred by 
convalescent plasma. More recent studies have demonstrated protection in SAM 
and NHPs with use of polyclonal and monoclonal antibodies [18]. The antibodies 
targeting EBOV GP mucin-like domain have been shown to protect 100% mice 
against lethal EBOV challenge [19]. 
The most effective approach to post-exposure immunotherapy consists on use of 
cocktails of monoclonal antibodies against epitopes of EBOV. Two cocktails demon-
strated significant protection in NHPs against EBOV infection: MB-003 and ZMapp. 
MB-003 comprise of three monoclonal antibodies, which were raised in mice 
immunized with virus of Venezuelan equine encephalitis containing GP (VEEV-GP) 
[20]. The antibodies 13C6 and 6D8 neutralized EBOV via complement pathway, 
while 13F6 was non-neutralizing. For further studies these antibodies were produced 
either as a human-mouse chimera (c) or humanized (h) form in the tobacco plant 
(Nicothiana benthamiana). MB-003 was tried in rhesus macaques (50 mg/kg i.v.) 
beginning at 24 or 48 hours after challenge, with three identical doses given ev-
ery 2–3 days. Such treatment provided 67% protection [20].
Another product — ZMapp — containing 3 chimeric monoclonal antibodies 
against EBOV GP epitopes (c13C6, c2G4 and c4G7), each produced in large 
quantities in Nicothiana benthamiana recently has been shown to confer survival 
benefit in NHPs when administered even 4–5 days after infection [21]. This for-
mulation was administered to three patients in 2014 and the conditions of two 
reportedly improved soon after they received it, while the third patient died [22]. 
Clearly more clinical experience is needed to clarify the question of efficacy of 
such treatment in EHF patients. Nevertheless, the U.S. government (NIH’s Na-
tional Institute of Allergy and Infectious Diseases, The Department of Defense’s: 
Defense Threat Reduction Agency and the HHS’Biomedical Advanced Research 
and Development Authority) has provided support for the development of this 
experimental treatment.
Next to post exposure immunotherapy several other EBOV-specific therapeu-
tics are under investigation in NHPs and SAM. Phosphorodiamidate morpholino 
oligomers (PMOs) are cell permeable nucleotide analogs, which bind specific se-
quences of EBOV mRNA and by steric hindrance prevent the translation of the 
viral mRNA [23]. The morpholino oligomers have been previously demonstrated 
highly stable, safe and effective therapeutics against coronaviruses and flavivirus-
es [24]. PMOs targeting EBOV VP24 and EBOV VP35 mRNAs have shown effica-
cy in mice and guinea pigs models of EBOV infection [25]. Moreover, AVI-6002 
(a combination of PMOs against EBOV VP24 and EBOV VP35 mRNAs), delivered 
30–60 min post-exposure (and daily s.c./i.p. or in i.v. injection of 40 mg/kg) 
protected >60% of rhesus macaques against lethal EBOV infection [23]. Clearly, 
PMOs due to its efficacy and good safety record may represent a viable therapeu-
tic strategy in EHF. Currently, AVI-6002 is in phase I clinical trials.
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Another strategy to inhibit EBOV replication is use of small interfering RNAs 
(RNAi), which interfere with translation by either sterically blocking specific mRNA 
or by triggering RNase H-mediated cleavage of the DNA/RNA duplex with subse-
quent inhibition of gene expression. The siRNA targeting the EBOV RNA polymerase 
L protein, encapsulated in bilayered liposomes, forming stable nucleic acid par-
ticles (SNALPs) has been developed by Tekmira Inc. (LNP-siRNA:TKM-Ebola) [26]. 
The SNALPs targeting EBOV polymerase L, VP24 and VP35 were tried on rhe-
sus macaques in four or seven doses following lethal challenge with EBOV. Two 
of three monkeys given four doses survived, while all four monkeys given seven 
doses survived otherwise lethal infection. Importantly, there were no evidence for 
serious side effects of that treatment, except mild elevations of liver transaminas-
es. Currently, LNP-siRNA:TKM-Ebola is in phase I clinical trials.
Only recently, a broad spectrum nucleoside analog BCX4430 (Immucillin-A) 
developed by BioCryst Pharmaceuticals in association with U.S. Army showed 
significant protection against wide variety of viruses, including EBOV in post-ex-
posure models in NHPs [27]. This compound inhibits viral polymerase function 
and acts as a non-obligate RNA chain terminator. In rhesus macaques challenged 
with EBOV, at a dose of 15 mg/kg, starting either 1, 24, and 48 hours after 
infection and continuing twice daily for next 14 days BCX4430 protected 83% 
animals in the 1-hour group, and 100% in the 24- and 48-hour groups [27]. Re-
garding high efficacy (but on the other hand the high number of doses required 
for protection) the issue of drug-related adverse effects should be obligatory ad-
dressed before clinical trials.
Several treatment options, not tested in NHPs so far, have shown efficacy in 
small animal models of EBOV infection. Endogenous plasma mannose-binding 
lectin (MBL), produced in the liver recognizes carbohydrate moieties (mannose, 
hexose) of external surface of microbes (pathogen associated molecular patterns, 
PAMPs), which are not present on host cells. Importantly, EBOV contains large 
amounts of mannose in GP, thus upon binding with the MBL it is inactivated 
through the lectin-dependent of complement cascade [28]. Human recombinant 
MBL (350 µg i.p. twice daily for 10 days) has been shown to protect 40% of mice 
exposed to EBOV [29].
Several small molecule inhibitors have also shown some efficacy in SAM of 
EBOV infection. A pyrazinecarboxamide derivative T-705 (favipiravir) developed 
by Toyama Chemical of Japan was reported to inhibit in vitro EBOV RNA-de-
pendent RNA polymerase and clear in vivo virus infection within four days of 
treatment initiated at day 6 post infection [30, 31]. Favipiravir was given in Oc-
tober 2014 to the French nurse, who contracted Ebola disease in Liberia and 
fully recovered. Notably, the compound JK-05 developed by Chinese company 
Sihuan Pharmaceutical with support of the Chinese Army, similar to favipiravir 
was available for Chinese health workers involved in 2014 West African Ebola 
outbreak.
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A variety of compounds with unclear mechanisms of action, like metal ion-
based therapeutic hexamminecobalt (III) chloride (Cohex), heterocyclic aromatic 
structures targeting late event in EBOV replication cycle — FGI-103, FGI-104, 
FGI-106, and reactive oxygen species scavenger — NSC 62914 have shown in-
hibitory actions on EBOV replication in vitro and protective effects in pre- and/
or post-exposure treatment in small animal models of EBOV infection [18, 32]. 
Interestingly, several adenosine analogues have been shown to inhibit the rep-
lication of Ebola virus in vitro, most probably by blocking the S-adenosyl-L-ho-
mocysteine hydrolase and thereby indirectly limiting methylation of the 5’ cap 
of viral mRNA. Noteworthy, mice treated thrice daily for 9 days (2.2–20 mg/kg) 
with carbocyclic 3-deazaadenosine, were protected against lethal EBOV challenge, 
moreover, it appeared that even single administration of the same substance, or 
another analogue, 3-deazaneplanocin A, provides equal or better protection, with-
out causing acute toxicity [33]. Despite very promising results of studies on SAM, 
the effectiveness of all these compounds in NHPs remain to be tested.
A whole bunch of compounds showed in vitro activity against EBOV. 
Brincidofovir (CMX001) is a prodrug — lipid conjugate of cidofovir, developed 
by Chimerix (Durham, NC) for the treatment of herpes simplex, cytomegalovi-
rus, adenovirus and smallpox infections (currently in phase III clinical trials). It 
is generally active again dsDNA viruses, however preliminary in vitro tests have 
shown its efficacy against EBOV, which is somehow surprising, as EBOV is not 
a DNA virus [34]. In October 2014 Chimerix received FDA approval for emergency 
investigational new drug application for the treatment of Ebola disease and same 
month was administered to two patients: first, critically ill patient, was given 
brincidofovir 6 days after onset of infection; he died four days later. The second 
patient, released from Nebraska Medical Center was pronounced Ebola-free. Re-
cently, brincidofovir as potential anti-EBOV drug entered phase II clinical trials.
LJ001, an aryl methyldiene rhodamine derivative was identified in vitro as 
efficient virus-cell entry inhibitor for variety of enveloped viruses (EBOV, HCV, 
HIV-1) [32]. Although, initial testing in mice did not show significant activity, pos-
sible further improvement of pharmacokinetic properties makes this compound 
promising future therapeutic.
Several compounds targeting molecules/pathways important for EBOV entry 
into cells have shown the efficacy in vitro: the inhibitors of Niemann Pick C1 
(NPC1) protein (e.g. U18666A), inhibitors of cathepsin L or B, HSP90 inhibitors 
[18, 32, 35]. There were also identified several anti-EBOV compounds with un-
clear mechanisms of action: -peptide immunoadhesins (possibly interfering with 
GP processing in cells), C-peptides (possibly preventing fusion of the virus to the 
host cell membrane), compound 7 (benzodiazepine derivative, possibly inhibiting 
early stages of virus entry to the cells) [18, 32].
Only recently, microRNA inhibitors (hsa-miR-1246, hsa-miR-320a and hsa-
miR-196b-5p) were found to ameliorate GP-dependent cell damage in vitro [36]. 
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This observation points to the novel mechanisms of EBOV cellular toxicity and 
possibly, opens new way for design of EHF therapies.
Interestingly, several known drugs approved for treatment of various diseases 
clearly showed strong in vitro anti-EBOV activities. Recently, estrogen receptor 
modulators (clomiphen, toremiphen) and several anti-dysrhythmic drugs (amio-
darone, dronedarone, verapamil) have been reported to inhibit EBOV cell entry, 
possibly by interfering with NPC1 activity. Also, antimalarial drug — chloroquine 
has been shown to disrupt EBOV entry and replication in vitro, as well as in-
crease survival rate in mice challenged with lethal EBOV infection [37–39]. Very 
recently, extensive search revealed over 50 drugs able to interfere with EBOV rep-
lication cycle in vitro [40]. Such observations triggered debate about the allowing 
fast track use of existing medicines, with known safety profiles as “repurposed” 
drugs for Ebola treatment [41]. 
Over the last few years we have witnessed the great advances in the devel-
opment of EBOV therapeutics. Although the most notably progress was done on 
the field of vaccines, also several promising post-exposure candidate drugs were 
developed. 
T a b l e  1
Potential specific anti-EBOV therapeutics showing efficacy in non-human primates (NHPs),  
small animal models (SAM) and in vitro. Detailed description — see text.
Efficient in NHPs ZMapp (cocktail of monoclonal antbodies)
MB-003 (cocktail of monoclonal antbodies)
Phosphoroamidate Morpholino Oligomers (PMOs)
LNP-siRNA:TKM-Ebola
BCX4430
Efficient in SAM rhMBL
pyrazinecarboxamide derivative T-705 (favipiravir)
JK-05
hexamminecobalt (III) chloride (Cohex)
FGI-103, FGI-104, FGI-106
NSC 62914
3-deazaneplanocin A
Efficient in vitro Brincidofovir
LJ001
NPC1 inhibitors (U18666A)
selected repurposed drugs (chloroquine, amiodarone, dronedarone,    
   clomiphen, toremiphen) 
HSP90 inhibitors
-peptide immunoadhesins
C-peptides
benzodiazepine derivative (compound 7)
specific microRNA inhibitors 
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There is a cause of optimism, that despite the ethical issues regarding use 
of investigational drugs in humans and problems with design and organization 
of clinical trials with patients with hemorrhagic fever, some of these drugs soon 
will become more widely available for emergency use and commercially available 
within next 5–10 years. 
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